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We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU)
continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant
anthracyclines. A total of 61 patients received a regimen consisting of VNB 25mgm
 2 on days 1 and 15, PTX 60mgm
 2 on days 1, 8
and 15 and continuous infusion of 5-FU at 200mgm
 2 every day. Cycles were repeated every 28 days. Disease response was
evaluated by both RECIST and World Health Organization (WHO) criteria. Objective responses were recorded in 39 of 61 patients
(64.0%) assessed by WHO and in 36 of 50 patients (72.0%) assessable by RECIST criteria. Complete remission occurred in 15
(24.6%) and 14 patients (28.0%), respectively. The median time to progression and overall survival of entire population was 10.6 and
27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was
myelosuppression (leucopenia grade 3/4 in 52.5% of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in
13.1%, skin in 3.3% and cardiac in 1.6% of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2%). The VNB, PTX and
5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.
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Breast cancer is the most commonly diagnosed cancer and remains
the first cause of cancer-related death in women in Italy (Negri
et al, 2001). In the management of patients with metastatic disease,
chemotherapy may offer effective palliation, and anthracyclines
are widely recognised as the most active drugs (Esteva et al, 2001;
Crown et al, 2002). The widespread use of these agents in the
adjuvant setting, however, limits their employment in disease
recurrence, thus demanding the testing of new effective regimens.
In the past decade, vinorelbine and taxanes have been shown to
generate a consistent level of activity in advanced breast cancer,
yielding as single agents overall response rates between 30.0 and
50.0% along with acceptable toxicity profiles. Both drugs were
demonstrated to be relatively non-crossresistant to anthracyclines
(Esteva et al, 2001; Crown et al, 2002).
Vinorelbine blocks the formation of the mitotic spindle
apparatus at the metaphase by inhibiting microtubule assembly
(Fellous et al, 1989). Conversely, paclitaxel promotes and stabilises
polymerised tubulin into nonfunctional microtubule bundles, thus
blocking the cells in the G2/M phase of the cell cycle (Manfredi and
Horwitz, 1984). The combination of vinorelbine and paclitaxel is
thought to create a total microtubule poison that offers theoretical
advantages deriving from the potential synergy between the two
drugs when given together. Preclinical data have shown that
paclitaxel and vinorelbine were synergistic in vitro (Photiou et al,
1997; Budman et al, 2000), while in vivo their combination
produced a significantly greater proportion of cell kill of
transplanted p388 murine leukaemia cells than either agent alone
(Knick et al, 1995). The combination of paclitaxel and vinorelbine
has been evaluated in a number of phase I and II trials. As a whole,
the results have been encouraging, with an overall response rate
between 47.4 and 67.0% (Martin et al, 1998; Tortoriello et al, 1998;
Culine et al, 1999; Ellis et al, 1999; Romero Acuna et al, 1999; Vici
et al, 2000; Ibrahim et al, 2001; Ballestrero et al, 2003).
Fluoropyrimidines, and 5-fluorouracil (5-FU) in particular, have
been employed for over 40 years to treat numerous solid tumours
including breast cancer (Venturini, 2002). Fluorouracil is an S-
phase-specific agent with a short serum half-life of 10–20min,
making it active only against a small proportion of tumour cells in
the S phase when administered via short intravenous bolus
injection. When it is given over an extended period of time, the
resulting greater number of actively dividing cells exposed to the
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sdrug warrants the administration of 5-FU as a continuous infusion
(Cameron et al, 1994; Regazzoni et al, 1996). In addition, due to
the modified plasma concentration profile, large cumulative
fluorouracil doses administered via continuous infusion are better
tolerated than bolus injection (Cameron et al, 1994; Regazzoni et al,
1996). The moderate myelotoxicity of infusional 5-FU allows its
combination with other myelotoxic agents. The theoretical
advantages of the association of infusional 5-FU with paclitaxel
and vinorelbine include (1) 5-FU has a different mechanism of
cytotoxicity, (2) its proposed mechanism of resistance is different
and (3) it possesses relatively nonoverlapping toxicity. The
therapeutic activity of fluorouracil combined with vinorelbine or
paclitaxel in metastatic breast cancer has been widely tested, and
high response rates (up to 70.0% as a first-line approach) have
been reported (Vredenburgh et al, 1998). To our knowledge, the
association of protracted infusion of 5-FU with both vinorelbine
and paclitaxel has never been tested. In a phase II trial we
conducted, biweekly vinorelbine associated with protracted 5-FU
infusion was found to be extremely active as a second- or third-line
approach in advanced breast cancer patients previously treated
with anthracyclines (Berruti et al, 2000). In view of these
encouraging results, we tested this combination in association
with paclitaxel as first-line treatment in advanced breast cancer
patients pretreated in adjuvant setting with anthracycline-contain-
ing regimens. The primary aim of the study was to evaluate the
activity of the combination regimen; the secondary aim was to
assess toxicity, time to progression (TTP) and overall survival
(OS).
PATIENTS AND METHODS
Patients
Women, 18 years of age or older, were eligible for the study if they
had histologically confirmed advanced breast cancer and disease
assessable according to the World Health Organization (WHO)
criteria of disease response (22). Other eligibility criteria included
good performance status (WHO grade 0–1), adequate bone
marrow reserve (WBC count X3.5 10
9l
 1, platelets X100 
10
9l
 1), adequate hepatic and renal function (hepatic enzymes and
bilirubin o2 upper limit of normal, serum creatinine within
normality) and an estimated life expectancy of at least 12 weeks.
Patients were excluded from the study who presented with
nonmalignant systemic disease or conditions that precluded them
from receiving study therapy (e.g. active infection, any clinically
significant arrhythmia, congestive heart failure or pregnancy) or
with CNS metastases or second primary malignancies (except in
situ carcinoma of the cervix or adequately treated basal cell
carcinoma of the skin), or who used any investigational agent 1
month before enrolment. All patients had to have received
adjuvant chemotherapy with an anthracycline-containing regimen.
Prior systemic chemotherapy for advanced disease and prior
exposure to either vinorelbine or taxanes were not allowed, but one
line of endocrine therapy in the metastatic setting was permitted.
The study was approved by the local ethics committee. Written
informed consent was obtained from all patients before starting
treatment.
Treatment schedule
Treatment consisted of: vinorelbine (Navelbine; Pierre Fabre
Pharma, Milan, Italy) 25mgm
 2 on days 1 and 15 every 28 days
given as a 10-min infusion in 100ml saline solution; paclitaxel
(Taxol; Bristol Myers Squibb, Rome, Italy) 60mgm
 2 on days 1, 8
and 15 every 28 days given as a 3-h infusion in 500ml normal
saline solution; 5-FU given at a daily dose of 200mgm
 2 as a
protracted continuous infusion using an elastomeric pump. All
patients had a central venous access. All drugs were administered
on an outpatient basis. Since preclinical data suggested that the
sequence of administration of paclitaxel and vinorelbine was
predictive for treatment efficacy (Photiou et al, 1997; Budman et al,
2000), vinorelbine infusion preceded paclitaxel infusion. Dose
modifications were performed as follows: in case of myelosuppres-
sion, if the WBC count was p2500ml
 1 and/or the platelet count
was less than 100000ml
 1, then 5-FU was continued but both
paclitaxel and vinorelbine at that day were omitted. If the blood
count had recovered after 1 week, full-dose vinorelbine and
paclitaxel were then administered. If the blood count had not
recovered, then both vinorelbine and paclitaxel were further
omitted, and the drug dose was subsequently reduced by 25%. In
the event of hand and foot syndrome, for mild to moderate
palmoplantar erythema (dryness and erythema with pain), patients
continued 5-FU; for severe palmoplantar erythema with blistering
and desquamation, 5-FU was interrupted until the erythema had
returned to grade 1 or less, and afterwards 5-FU was restarted at
full doses. For WHO grade 1 or 2 diarrhoea, antidiarrhoeal agents
were prescribed; for persistent diarrhoea, 5-FU, but not vinor-
elbine or paclitaxel, was discontinued for 1 week. In case of
resolution, 5-FU was restarted at full doses; if symptoms persisted,
a 25% dose reduction was performed. For grade 3 or 4 diarrhoea,
5-FU was withdrawn until the diarrhoea had returned to grade 1 or
less, and afterwards 5-FU was restarted with a 50% reduction in
dosage. In patients with grade 2 mucositis, infusional 5-FU was
stopped for 1 week, then restarted at full doses; if symptoms
recurred, a 25% dose reduction was performed. For grade 3 or 4
mucositis, 5-FU was withdrawn until complete resolution (grade 0)
and restarted with a 25% reduction in dosage. Vinorelbine and
paclitaxel doses were delayed for 1 week in case of grade 2
neurotoxicity; in the event of grade 3 neurotoxicity, vinorelbine
was reduced by 50% in subsequent cycles, whereas paclitaxel was
withdrawn.
Relative dose intensity was defined as the actual weekly doses of
vinorelbine, paclitaxel and 5-FU at the end of treatment divided by
the planned weekly dose. Supportive care could include blood
transfusion and administration of analgesics, antiemetics and
growth factors as appropriate. The prophylactic use of G-CSF to
maintain dose intensity was not permitted.
Assessment of response and toxicity
Pretreatment evaluation included medical history and physical
examination, complete blood cell count, serum chemistries, liver
function tests, ECG, echocardiography, tumour marker evaluation
(CA 15-3) and staging studies appropriate to define the extent of
metastatic disease, including chest X-ray, abdominal ultrasono-
graphy, thoracic and/or abdominal computed tomography scan-
ning and bone scanning. Clinical monitoring was performed once
weekly; complete blood cell counts, serum electrolytes and liver
function tests were performed every 2 weeks. Toxicity was
evaluated according to the WHO criteria (Miller et al, 1981).
Antitumour activity was evaluated every 3 months on all
measurable lesions, and all patients were scheduled for at least a
2-month treatment in order to be eligible for assessment of tumour
response. The response obtained needed confirmation after at least
1 month. In patients with tumour response or stable disease, the
treatment was planned to be continued for up to 6 months;
thereafter, maintenance or no endocrine therapy (in patients with
ERþ tumours) was based on the clinician’s choice. After the
completion of chemotherapy, the patients were monitored every 3
months.
Tumour response was classified according to either the WHO
criteria (Miller et al, 1981) or the RECIST criteria (Therasse et al,
2000), as detailed elsewhere. All deaths and treatment discontinua-
tions (for toxicity or patient refusal) were considered as treatment
failures. Time to progression was calculated from the beginning of
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progressive disease. Survival was dated from the first day of
treatment until death or was censored on the date of the last
follow-up appointment.
Statistical analysis
The primary study end point was the assessment of the response
rate (intent-to-treat analysis). According to the optimal two-stage
phase II study design of Simon (1989), the sample size was
assessed in order to refuse response rates p40.0% (p0) and to
provide a statistical power of 80.0% in assessing the activity of the
regimen as a 60.0% response rate.
A maximum of 46 consecutive cases were required with 16 cases
in the first stage and 30 in the second stage. If seven responses or
fewer were observed in the first stage, then the trial was stopped
with the conclusion that the success rate was less than 40.0%. If
greater than seven responses were observed, then the trial was
continued to the second stage to recruit a further 30 consecutive
patients. Since both WHO and RECIST criteria were employed to
assess disease response, the trial was planned to end when at least
46 cases assessable with the two response criteria had been
consecutively enrolled. Response duration and survival were
assessed using Kaplan–Meier survival curves. A two-sided
significance of the 5.0% level was applied to all tests. All statistical
analyses were performed using the Statistica for Windows software
program.
RESULTS
From January 2000 to April 2002, 61 consecutive patients were
enrolled in the study. Of these, all were assessable according to
WHO criteria and 50 patients were also assessable according to
RECIST response criteria. The demographic data, metastatic
tumour sites and prior therapies are listed in Table 1. In all, 34
(55.8%) patients had one metastatic site and 27 (44.2%) had
multiple metastases involving two or more organ systems.
Predominant visceral sites were found in 43 patients (70.5%),
whereas predominant bone and soft tissue sites were found in 11
(14.7%) and seven (11.5%), respectively.
Treatment activity
The best responses recorded for each patient are listed in Table 2.
According to the WHO criteria, an objective regression was
recorded in 39 women (64.0% (95% confidence interval (CI) 51.7–
76.3%)), of which 15 (24.6%) attained a complete clinical response.
The distribution of responses according to the disease site is listed
in Table 3. Overall response in patients with only one disease site
(21 out of 35, 60.0%) was similar to that of patients bearing
multiple sites of disease (17 out of 26, 65.4%). At the last follow-up
appointment (30 November 2003), 47 patients (77.0%) showed
disease progression and 33 (54.1%) had died. Median TTP and OS
of the entire group was 10.6 and 27.3 months, respectively. Median
duration of disease response was 10.2 months (14.8 months in
complete responders). Stratifying patients according to the
disease-free interval (DFI), disease response occurred in nine out
of 18 patients (50.0%) with DFI less than 2 years while it obtained
in 30 out of 43 patients (69.8%) with DFI more than 2 years
(P¼0.14). The corresponding median TTP was 6.7 and 13.8
months in the two groups, respectively (P¼0.003).
The treatment activity evaluated by RECIST criteria was 36 out
of 50 assessable cases with a disease response (72.0% (95% CI
59.3–84.7%)) and 14 (28.0%) with a complete clinical response.
Median TTP and OS in this patient subset was 10.0 and 25.5
months, respectively. Median duration of disease response was 9.4
months (17.8 months in complete responders). Table 1 Patient characteristics
Characteristics Patients (N¼61)
Age (years)
Median (range) 54.3 (30.6–70.7)
Postmenopause 54 (88.5%)
Premenopause 7 (11.5%)
Performance status
a
0 40 (65.6%)
1 14 (22.9%)
2 5 (8.2%)
3 2 (3.3%)
Oestrogen receptor status
Positive 30 (49.2%)
Negative 26 (42.6%)
Unknown 5 (8.2%)
Disease-free interval (months) 43.5 (9–265.7)
Previous treatments
Surgery 60 (98.4%)
Radiation therapy 26 (42.6%)
Adjuvant anthracycline chemotherapy 61 (100.0%)
Previous endocrine therapy
Adjuvant 27 (44.3%)
Advanced disease 11 (18.0%)
Disease sites
Skin/lymph nodes 20 (32.8%)
Bone 27 (44.3%)
Lung 29 (47.5%)
Liver 22 (36.1%)
Other 3 (4.9%)
Number of sites of disease
1 34 (55.8%)
2 16 (26.2%)
3 10 (16.4%)
4 1 (1.6%)
aECOG scale.
Table 2 Treatment activity
WHO criteria RECIST criteria
Patients (N¼61) Patients (N¼50)
Not evaluable 5 (8.2%) 4 (8.0%)
Reasons
Treatment refusal 2 (3.3%) 1 (2.0%)
Death 1 (1.6%) 1 (2.0%)
Toxicity 2 (3.3%) 2 (4.0%)
Progressive disease 6 (9.8%) 4 (8.0%)
Stable disease 11 (18.0%) 6 (12.0%)
Partial response 24 (39.4%) 22 (44.0%)
Complete response 15 (24.6%) 14 (28.0%)
Overall response 39 (64.0%) 36 (72.0%)
(95% Confidence interval) (51.7–76.3%) (59.3–84.7%)
Table 3 Disease response according to sites of disease (WHO)
Disease site CR PR SD PD
Skin/lymph (total no., n¼19) 8 (42.1%) 6 (31.6%) 2 (10.5%) 3 (15.8%)
Bone (total no., n¼27) 2 (7.4%) 9 (33.3%) 11 (40.8%) 5 (18.5%)
Lung (total no., n¼29) 7 (24.1%) 10 (34.5%) 8 (27.6%) 4 (13.7%)
Liver (total no., n¼22) 9 (40.9%) 4 (18.2%) 3 (13.6%) 6 (27.2%)
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A total of 309 cycles of therapy were administered (median six
cycles; range 1–6). Associated side effects are reported in Table 4.
Haematological toxicity was the most frequent severe toxicity.
Grade 3–4 leucopenia was observed in 52.5% of patients; grade 3–
4 Hb toxicity was recorded in 6.6% of patients. Gastrointestinal
toxicities included grade 3 nausea and vomiting (6.6%), grade 3
mucositis (11.5%) and grade 3 hepatic toxicity (3.3%). Two
patients experienced serious hypersensitivity reactions after the
second paclitaxel infusion. Paclitaxel was therefore interrupted in
these patients, while vinorelbine and 5-FU were maintained. A
total of 18 patients (29.5%) developed neurologic toxicity, with
grades 2 and 3 recorded in five cases (8.2%), and dose-limiting
toxicity in three. It was noteworthy that more than 70.0% of
patients did not develop alopecia.
In a total of 24 (39.3%) patients, 64 courses (20.7%) were
delayed 1 week, and eight courses (2.6%) (six patients (9.8%)) were
delayed 2 weeks due to haematological toxicity. Paclitaxel was
reduced or omitted in 39 patients (63.9%) (107 courses (34.6%)),
while vinorelbine and 5-FU were reduced or omitted in 29 (47.5%)
(64 courses (20.7%)) and in 37 (60.6%) (99 courses (32.0%)),
respectively. Leucopenia was the most frequent cause of dose
reduction/omission of the three drugs. Paclitaxel was reduced in
three patients (six cycles) due to neurotoxicity; 5-FU was reduced/
omitted in four (12 courses) due to gastrointestinal toxicity
(diarrhoea, mucositis), in one patient (two courses) due to skin
toxicity and in seven (12 courses) due to central venous access
problems (delayed positioning in five patients, catheter infection
or thrombosis in two). A total of 42 patients (68.8%) ended the
treatment plan (six cycles), four (6.6%) received five cycles, two
(3.3%) received four cycles, seven (11.5%) received three cycles,
four (6.6%) received two cycles and two (3.3%) received one cycle.
The reasons for early stopping treatment were disease progression
(six patients), leucopenia (six patients), mucositis (one patient),
hepatic toxicity (one patient), cardiac toxicity (one patient),
patient refusal (three patients) and sudden death (one patient).
Dose intensity was calculated for each patient and for each drug.
The median dose intensity of vinorelbine was 10.7mgweek
 1
(85.7% of planned dose), the median dose intensity of paclitaxel
was 37.2mgweek
 1 (82.7%) and the median dose intensity of 5-FU
was 1187.9mgweek
 1 (84.8%).
DISCUSSION
The rationale for administering vinorelbine in association with
paclitaxel in anthracycline-pretreated breast cancer patients
centres mainly on the documented activity of the two drugs in
anthracycline refractory patients (Crown et al, 2002) and on the
synergism of the cytotoxic effects of the two drugs in preclinical
models (Photiou et al, 1997; Budman et al, 2000). The addition of
infusional 5-FU might further increase the activity of this
combination.
In a previous study our cooperative group conducted, biweekly
vinorelbine associated with continuous 5-FU infusion was found to
be well tolerated and highly active in a subgroup of heavily
pretreated patients (Berruti et al, 2000). In the present study,
paclitaxel was added to this regimen. Since weekly paclitaxel
infusion has been reported to be more active than 3-weekly
administration (Seidman et al, 1998), paclitaxel was administered
on a sustained weekly schedule.
Our results suggest that vinorelbine, paclitaxel and 5-FU have a
high antitumoral activity in anthracycline-pretreated patients, as
indicated by the overall response rate, median TTP and OS.
This trial was designed when the new RECIST criteria for
response assessment had just been proposed to replace the WHO
criteria. So we thought it would be interesting to look at both
criteria to assess disease response. Since the RECIST criteria are
more restrictive than the WHO criteria (e.g. patients with bone
metastases alone are admitted on WHO criteria but not on RECIST
criteria), the number of enrolled cases eligible for WHO response
exceeded by 20% the number of enrolled cases eligible for RECIST
response. The overall response rate in the 50 patients eligible for
assessment by either WHO or RECIST criteria was quite similar,
but when all consecutively assessable patients were considered, the
disease response assessed by the RECIST criteria was slightly
higher than that assessed by the WHO criteria. The difference is
mainly due to the inclusion of bone-only metastases in patients
eligible on WHO criteria, which are notoriously less responsive
than visceral metastases (Coleman and Rubens, 1987). The 64.0%
response rate recorded in this trial using the WHO criteria (72.0%
on the RECIST criteria) is noteworthy when we consider that all
patients had previously received anthracyclines. The therapeutic
activity of the regimen was not influenced by adverse prognostic
factors such as predominant visceral disease or multiple metastatic
sites. Conversely, patients with short DFI had a tendency to low
disease response and shorter TTP as opposed to their counter-
parts, thus confirming previous observations showing that DFI is
an important predictor of poor outcome in metastatic breast
cancer patients treated with first-line therapy (Kramer et al, 2000).
The proportion of patients attaining a clinical complete response
(24.6 and 28.0% by WHO and RECIST criteria, respectively) is
quite impressive. Complete responses were observed in all
metastatic sites, and particularly in the liver. Complete clinical
response was durable (20 months on average), a noteworthy
finding since liver metastases are associated with poor prognosis
(Atalay et al, 2003).
As concerns treatment tolerability, leucopenia was the most
frequent and dose-limiting side effect associated with the regimen.
WHO grade 3 or 4 WBC toxicity occurred in 52.5% of patients,
although it was never complicated by sepsis requiring hospitalisa-
tion. Since the prophylactic use of G-CSF was not permitted,
leucopenia caused frequent reduction/omission, mainly of pacli-
taxel and/or vinorelbine. The frequency of bone marrow depres-
sion observed here did not differ from that reported in other phase
II studies testing the association of paclitaxel and vinorelbine
(Martin et al, 1998; Tortoriello et al, 1998; Culine et al, 1999; Ellis
et al, 1999; Romero Acuna et al, 1999; Vici et al, 2000; Ibrahim et al,
2001; Ballestrero et al, 2003). This suggests that 5-FU may have
influenced this side effect only marginally. 5-Fluorouracil was less
frequently reduced due to haematologic toxicity, but drug doses
were adjusted due to mucositis, central catheter complications and,
less frequently, because of hand and foot syndrome. Neurotoxicity
is an expected side effect of both paclitaxel and vinorelbine; this
side effect may potentially be increased by the association of the
Table 4 Toxicity
Grade 0 1234
Leucopenia 7 (11.5%) 6 (9.8%) 16 (26.2%) 22 (36.1%) 10 (16.4%)
Anaemia 23 (37.7%) 25 (41.0%) 9 (14.7%) 4 (6.6%) —
Thrombocytopenia 57 (93.5%)
1 (1.6%)
1 (1.6%) 1 (1.6%) 1 (1.6%)
Nausea/vomiting 34 (55.7%) 17
(27.9%)
6 (9.8%) 4 (6.6%) —
Diarrhoea 48 (78.7%) 9 (14.7%) 3 (4.9%) 1 (1.6%) —
Mucositis 40 (65.6%) 8 (13.1%) 6 (9.8%) 7 (11.5%) —
Hepatic 59 (96.7%) — — 2 (3.3%) —
Myalgias 55 (90.2%) 4 (6.6%) 2 (3.2%) — —
Fever 55 (90.2%) 3 (4.9%) 3 (4.9%) — —
Neurological 43 (70.5%) 13 (21.3%) 4 (6.6%) 1 (1.6%) —
Cardiac 56 (91.8%) 4 (6.6%) — 1 (1.6%) —
Skin 48 (78.6%) 7 (11.5%) 4 (6.6%) 2 (3.3%) —
Alopecia 44 (72.1%) 1 (1.6%) 2 (3.3%) 14 (23.0%) —
No patients had lung or bladder toxicity.
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stwo drugs. A total of 18 patients developed neurotoxicity, but most
showed only minor neurologic impairment. Grade 2–3 neurotoxi-
city was observed in five cases, and only three required transient
paclitaxel withdrawal. Other reported treatment-related toxicities
were clinically unremarkable.
In conclusion, the association of paclitaxel, vinorelbine and
infusional 5-FU shows favourable activity and toxicity profiles and
it may provide a suitable therapeutic option in advanced breast
cancer patients pretreated with anthracyclines. Although we were
unable to consistently deliver the planned full drug dose in all
patients, the activity of this combination was significant and the
responses were durable. Whether 5-FU could offer additional
benefit to the association of paclitaxel and vinorelbine needs to be
addressed in a randomised clinical trial.
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